HEICO Corp. 10-Q Summary: Period Ended July 31, 1995
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 31, 1995, and the nine-month period ended on that date. HEICO Corporation operates through two primary segments: HEICO Aerospace Corporation (aerospace products and services) and MediTek Health Corporation (medical diagnostic imaging services). The company is incorporated in Florida with principal executive offices in Hollywood, FL.
Key Financial Metrics
| Metric | Nine Months Ended July 31, 1995 | Nine Months Ended July 31, 1994 | Three Months Ended July 31, 1995 | Three Months Ended July 31, 1994 |
|---|---|---|---|---|
| Net Sales | $29,725,000 | $23,412,000 | $10,447,000 | $8,702,000 |
| Net Income | $1,942,000 | $1,319,000 | $721,000 | $448,000 |
| Diluted EPS | $0.74 | $0.52 | $0.26 | $0.18 |
| Operating Income | $3,003,000 | $1,311,000 | $1,062,000 | $677,000 |
| Cash from Operations | $4,560,000 | $1,033,000 | N/A | N/A |
| Cash and Equivalents (End of Period) | $5,343,000 | $2,286,000 | $5,343,000 | $2,286,000 |
| Total Debt (Current + Long-term) | $8,141,000 | $5,456,000 | $8,141,000 | $5,456,000 |
| Aerospace Gross Margin (9mo) | 31.6% | 28.6% | 31.9% | 31.5% |
| MediTek Gross Margin (9mo) | 32.0% | 31.7% | 27.0% | 32.1% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 27% year-over-year for the nine-month period, driven by a 36% increase in Aerospace sales and a 14% increase in MediTek sales.
- Profitability: Net income rose 47% year-over-year. Excluding a one-time accounting change benefit in the prior year, net income improved 107%.
- Segment Performance:
- Aerospace: Sales volume increased significantly, and gross margins improved due to higher-margin product sales and manufacturing cost reductions.
- MediTek: Q3 sales decreased 6% due to the discontinuation of the medical therapy equipment line, though imaging services revenue grew. Nine-month sales grew 14% due to new facility openings and MRI capabilities.
- Expenses: Selling, general, and administrative (SG&A) expenses increased in absolute dollars but declined as a percentage of sales (20.0% vs. 23.1% prior year) due to expense reduction programs.
- Debt: Total debt increased to $8.14 million from $5.46 million, primarily due to additional debt associated with MediTek center acquisitions.
Guidance, Outlook, and Risks
Management Commentary: Management attributes improved results to increased sales volumes in both segments. HEICO Aerospace's backlog remained stable at $15.5 million, with increases driven by commercial airline customers. MediTek continues to expand its diagnostic imaging footprint.
Liquidity: The company increased its credit facility to $7 million in June 1995, with approximately $6.3 million available for borrowing as of July 31, 1995. Cash provided by operating activities was strong at $4.56 million for the nine-month period.
Risks and Contingencies:
- Legal Proceedings: Two subsidiaries are involved in pending litigation with United Technologies Corporation. HEICO has filed counterclaims seeking compensatory and punitive damages.
- Regulatory Risk (MediTek): A Florida state court ruled that fee caps on diagnostic imaging services are unconstitutional. However, the State has appealed. If the caps are reinstated retroactively, it could materially adversely impact MediTek, which generated approximately 44% of its operating income from Florida operations.
Unusual Items: A 10% stock dividend was declared in May 1995 and paid in July, resulting in a $3.24 million charge to retained earnings. Historical per-share data has been restated to reflect this.
Investor Verification Checklist
- Verify the status of the Florida State Court appeal regarding diagnostic imaging fee caps and potential retroactive application.
- Monitor the progress of the litigation and counterclaims against United Technologies Corporation.
- Confirm the sustainability of HEICO Aerospace's gross margin improvements (31.6% vs 28.6% prior year).
- Review the impact of the discontinued medical therapy equipment line on future MediTek revenue projections.
- Assess the utilization of the expanded $7 million credit facility given the increase in total debt.